Where is the 12th National Moot Court Competition 2026 held?

The competition is held in Hubballi, IND.

What is the eligibility level for participants in this competition?

The competition is open to college-level participants.

What is the format of the 12th National Moot Court Competition 2026?

The competition is a moot court format, designed to simulate courtroom proceedings.

12th National Moot Court Competition 2026

May 23–24, 2026Hubballi, IndiaIn-person

ConcludedRegistration closed

The 12th National Moot Court Competition 2026 is an annual event held in Hubballi, IND, designed to foster legal acumen and advocacy skills among college students. This competition provides a platform for participants to engage with complex legal issues, hone their research abilities, and present compelling arguments in a simulated courtroom environment. It serves as a crucial training ground for future legal professionals, emphasizing critical thinking and persuasive communication.

Country perspectives

Where the most-relevant 1 countries stand on the dominant committee topic. Click through for the full country profile.

India

Host nation and a significant contributor to the global legal education landscape.

Role in topic

As the host country, IND provides the venue and institutional support for the competition, reflecting its commitment to legal education and the development of future legal professionals. The competition contributes to the legal discourse within IND and beyond.

Topics & background

The history behind each committee topic and the states that shape it.

International Intellectual Property: Harmonization and North-South Tensions

The modern international intellectual property (IP) regime was consolidated in 1995 with the entry into force of the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which set minimum standards for patents, copyrights, trademarks, and trade secrets across all WTO members. TRIPS built on earlier instruments such as the Paris Convention (1883) and the Berne Convention (1886), administered by the World Intellectual Property Organization (WIPO), but went further by tying IP protection to the binding WTO dispute settlement system. Developing countries accepted TRIPS in exchange for concessions on agriculture and textiles, a bargain many later judged unequal. Since then, the regime has been contested on several fronts. The 2001 Doha Declaration on TRIPS and Public Health affirmed the right of states to issue compulsory licenses for essential medicines, a flexibility that became central during the HIV/AIDS crisis and again during COVID-19, when India and South Africa led an unsuccessful push for a broad TRIPS waiver on vaccines. Bilateral and plurilateral 'TRIPS-plus' agreements pushed by the United States and the European Union have extended protections beyond WTO minimums, while China's rapid emergence as both a major patent filer and a target of enforcement complaints has reshaped the politics of IP. Today, debates center on access to medicines, AI-generated works, traditional knowledge, and whether the regime adequately balances innovation incentives against public-interest exceptions.

Key players

Biotechnology Disputes in International Trade and Regulation

Biotechnology has been a recurring flashpoint in international economic law since the commercialization of genetically modified organisms (GMOs) in the 1990s. The landmark WTO dispute EC – Biotech (DS291/292/293), brought by the United States, Canada, and Argentina against the European Communities in 2003, challenged the EU's de facto moratorium on GMO approvals and national-level bans by member states. The 2006 panel report found the EU's delays inconsistent with the SPS Agreement, but did not resolve the deeper regulatory divide between jurisdictions that treat biotech products as substantially equivalent to conventional counterparts and those that apply a precautionary approach. The Cartagena Protocol on Biosafety (2003), a supplement to the Convention on Biological Diversity, established the principle of advance informed agreement for transboundary movements of living modified organisms, but the United States, the world's largest producer of GM crops, is not a party. New frontiers — gene editing via CRISPR, synthetic biology, gene drives, and biotech vaccines — have reopened these debates. The EU's 2018 Court of Justice ruling treating gene-edited organisms as GMOs, ongoing negotiations on digital sequence information under the CBD, and disputes over labeling and import approvals continue to pit exporters against precautionary regulators, while developing countries weigh food-security benefits against biosafety and dependency concerns.

Key players

Patent Eligibility: Subject Matter, Software, and Life Sciences

Patent eligibility — the threshold question of what kinds of inventions may be patented at all — has become one of the most contested doctrinal areas in IP law. TRIPS Article 27 requires members to make patents available in 'all fields of technology' but permits exclusions for diagnostic, therapeutic, and surgical methods, as well as plants and animals other than microorganisms. National courts have used this latitude very differently. In the United States, the Supreme Court's decisions in Mayo v. Prometheus (2012), AMP v. Myriad Genetics (2013), and Alice v. CLS Bank (2014) sharply narrowed eligibility for natural phenomena, isolated DNA, and abstract ideas implemented on computers, generating persistent uncertainty in software and diagnostics. Elsewhere, India's Section 3(d) of the Patents Act, upheld in Novartis v. Union of India (2013) over the cancer drug Glivec, bars patents on new forms of known substances absent enhanced efficacy — a flexibility praised by access-to-medicines advocates and criticized by innovator industries. The European Patent Office applies its own technical-character test for software and excludes methods of medical treatment. New questions are now emerging around AI-generated inventions (the DABUS cases across multiple jurisdictions), CRISPR-edited organisms, and second medical uses. The result is a fragmented global landscape in which the same invention may be patentable in one jurisdiction and ineligible in another.

Key players

Jurisdiction in Cross-Border Disputes

Jurisdiction — the authority of a state's courts or regulators to adjudicate a matter — has grown increasingly contested as commerce, data, and harm flow across borders with little regard for territorial lines. Classical public international law recognized jurisdiction primarily on the basis of territoriality, nationality, the protective principle, and (in narrow cases) universality, as articulated in the Lotus case (PCIJ, 1927). In private international law, instruments such as the Brussels I Regulation in the EU and the Hague Conventions on Choice of Court (2005) and on Recognition and Enforcement of Judgments (2019) have sought to coordinate competing claims, but global harmonization remains incomplete. Contemporary disputes have stretched these frameworks. The extraterritorial reach of U.S. sanctions and securities law, the EU's General Data Protection Regulation, China's data and anti-foreign-sanctions laws, and India's evolving rules on e-commerce and digital intermediaries have produced overlapping and sometimes conflicting claims of authority. Courts have grappled with internet defamation, transnational antitrust (e.g., the EU's Google rulings, the U.S. FTAIA jurisprudence), business-and-human-rights litigation against parent companies (Vedanta, Okpabi in the UK Supreme Court), and arbitration-treaty disputes. The result is intensifying jurisdictional friction, forum shopping, and a growing need for clearer rules on recognition, enforcement, and the limits of extraterritoriality.

Key players

Data Sovereignty and Cross-Border Data Flows

Data sovereignty — the claim that data generated within a state's territory should be governed by that state's laws — has emerged as a central axis of digital geopolitics. The European Union set the modern template with the General Data Protection Regulation (2018), which combines extraterritorial application with strict conditions on international transfers. The Court of Justice's Schrems I (2015) and Schrems II (2020) judgments invalidated successive EU-U.S. data transfer frameworks over concerns about U.S. surveillance, leading to the 2023 EU-U.S. Data Privacy Framework, itself under legal challenge. Other powers have advanced distinct models. China's Cybersecurity Law (2017), Data Security Law (2021), and Personal Information Protection Law (2021) impose strong localization and security-review requirements. Russia, Vietnam, and Indonesia have adopted localization mandates of varying scope. India's Digital Personal Data Protection Act (2023) takes a lighter approach to localization than earlier drafts but retains government discretion over restricted jurisdictions. At the WTO, the Joint Statement Initiative on E-Commerce is negotiating disciplines on data flows and localization, while the African Union's Malabo Convention and Latin American frameworks chart additional paths. The core tension is between the economic logic of open data flows, the privacy and security rationales for control, and the strategic dimension of who governs critical digital infrastructure.

Key players

Biopiracy and the Protection of Genetic Resources and Traditional Knowledge

Biopiracy refers to the appropriation — typically through patents — of genetic resources or traditional knowledge from (often Global South) communities without prior informed consent or equitable benefit sharing. Iconic cases shaped the debate: U.S. patents on turmeric (revoked in 1997 after a challenge by India's CSIR), neem (revoked by the European Patent Office in 2005), basmati rice (RiceTec patent narrowed in 2001), and the Hoodia cactus used by the San people of southern Africa. These episodes exposed how patent offices in industrialized countries could grant rights over knowledge or materials that were neither novel nor locally originated. The principal international response is the Convention on Biological Diversity (1992) and its Nagoya Protocol on Access and Benefit-Sharing (2014), which require prior informed consent and mutually agreed terms for access to genetic resources. WIPO's Intergovernmental Committee on Genetic Resources, Traditional Knowledge and Folklore negotiated for over two decades, culminating in the 2024 WIPO Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge, which introduces a mandatory disclosure requirement in patent applications. Implementation challenges remain: digital sequence information (DSI) complicates physical-access regimes, enforcement of benefit-sharing is uneven, and the United States is not a CBD party. Defensive tools such as India's Traditional Knowledge Digital Library have helped, but structural asymmetries between resource-rich and technology-rich states persist.

Key players